Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free LIXT Stock Alerts

Lixte Biotechnology (LIXT) Financials

Lixte Biotechnology logo
$7.51 +0.30 (+4.16%)
Closing price 07/2/2026
Extended Trading
$7.51 0.00 (0.00%)
As of 07/2/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Lixte Biotechnology

Annual Income Statements for Lixte Biotechnology

This table shows Lixte Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.85 -2.13 -1.81 -2.13 -2.44 -3.26 -6.73 -6.31 -5.09 -3.59 -6.08
Consolidated Net Income / (Loss)		 -2.85 -2.13 -1.81 -2.13 -2.44 -3.26 -6.73 -6.31 -5.09 -3.59 -6.01
Net Income / (Loss) Continuing Operations		 -2.85 -2.13 -1.81 -2.13 -2.44 -3.26 -6.73 -6.31 -5.09 -3.59 -6.01
Total Pre-Tax Income 		-2.85 -2.13 -1.81 -2.13 -2.44 -3.26 -6.73 -6.31 -5.09 -3.59 -6.01
Total Operating Income		 -2.65 -2.13 -1.81 -2.14 -2.49 -3.27 -6.72 -6.31 -5.09 -3.57 -5.11
Total Gross Profit		 0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 2.85 2.13 1.81 2.14 2.49 3.27 6.72 6.31 5.09 3.57 5.11
Selling, General & Admin Expense		 0.75 1.26 1.34 2.10 1.67 1.49 4.25 3.69 4.19 2.85 4.85
Research & Development Expense		 2.09 0.87 0.47 0.04 0.82 1.22 1.74 1.35 0.90 0.73 0.25
Total Other Income / (Expense), net		 -0.21 0.00 0.00 0.00 0.05 0.00 -0.01 -0.00 0.00 -0.01 -0.90
Interest Expense		 - - - - 0.00 0.00 0.01 0.01 0.02 0.02 0.01
Interest & Investment Income		 0.00 0.00 0.00 0.00 0.05 0.00 0.00 0.01 0.02 0.01 0.01
Other Income / (Expense), net		 -0.21 - - - - 0.00 -0.00 -0.00 0.00 -0.00 -0.90
Preferred Stock Dividends Declared		 0.00 - - - - - - - - 0.00 0.07
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - - - - - 0.00 0.00
Weighted Average Basic Shares Outstanding		 46.79M 47.88M 55.82M 58.80M 11.17M 11.28M 13.47M 1.58M 1.92M 2.68M 11.62M
Diluted Earnings per Share		 ($0.06) ($0.04) ($0.03) ($0.04) ($0.22) ($0.29) - ($3.99) ($2.66) ($1.59) ($1.26)
Weighted Average Diluted Shares Outstanding		 46.79M 47.88M 55.82M 58.80M 11.17M 11.28M 13.47M 1.58M 1.92M 2.25M 4.84M
Weighted Average Basic & Diluted Shares Outstanding		 46.79M 47.88M 55.82M 58.80M 11.17M 11.28M 13.47M 16.66M 2.25M 2.68M 11.62M

Quarterly Income Statements for Lixte Biotechnology

This table shows Lixte Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.02 -1.03 -0.97 -1.01 -0.99 -0.62 -0.71 -0.78 -2.03 -2.56 -1.94
Consolidated Net Income / (Loss)		 -1.02 -1.03 -0.97 -1.01 -0.99 -0.62 -0.71 -0.78 -1.98 -2.54 -1.99
Net Income / (Loss) Continuing Operations		 -1.02 -1.03 -0.97 -1.01 -0.99 -0.62 -0.71 -0.78 -1.80 -2.73 -1.99
Total Pre-Tax Income 		-1.02 -1.03 -0.97 -1.01 -0.99 -0.62 -0.71 -0.78 -1.80 -2.73 -1.99
Total Operating Income		 -1.02 -1.03 -0.97 -1.01 -0.98 -0.61 -0.71 -0.77 -1.80 -1.82 -1.99
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 1.02 1.03 0.97 1.01 0.98 0.61 0.71 0.77 1.80 1.82 1.99
Selling, General & Admin Expense		 0.71 1.71 0.85 0.80 0.62 0.58 0.62 0.71 1.75 1.77 1.65
Research & Development Expense		 0.13 0.15 0.12 0.21 0.36 0.03 0.09 0.06 0.05 0.05 0.33
Total Other Income / (Expense), net		 0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 0.00 -0.90 -0.00
Interest Expense		 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Interest & Investment Income		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Income / (Expense), net		 -0.00 -0.00 -0.00 0.00 -0.00 -0.00 0.00 0.00 -0.00 -0.90 -0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - - 0.00 - - - -0.06
Basic Earnings per Share		 ($0.49) ($0.54) ($0.43) ($0.45) ($0.44) ($0.23) ($0.29) ($0.29) ($0.33) - ($0.18)
Weighted Average Basic Shares Outstanding		 2.07M 1.92M 2.25M 2.25M 2.25M 2.68M 2.47M 2.72M 6.17M 11.62M 10.89M
Diluted Earnings per Share		 ($0.49) ($0.54) ($0.43) ($0.45) ($0.44) ($0.23) ($0.29) ($0.29) ($0.33) ($0.35) ($0.18)
Weighted Average Diluted Shares Outstanding		 2.07M 1.92M 2.25M 2.25M 2.25M 2.25M 2.47M 2.72M 6.17M 4.84M 10.89M
Weighted Average Basic & Diluted Shares Outstanding		 2.25M 2.25M 2.25M 2.25M 2.25M 2.68M 2.68M 4.56M 5.70M 11.62M 12.38M

Annual Cash Flow Statements for Lixte Biotechnology

This table details how cash moves in and out of Lixte Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.02 0.17 1.11 2.97 -1.67 2.47 -0.25 0.53 -1.15 -3.16 4.07
Net Cash From Operating Activities		 -2.18 -1.68 -1.41 -1.51 1.67 -2.13 -4.14 -4.61 -4.29 -3.16 -3.07
Net Cash From Continuing Operating Activities		 -2.18 -1.68 -1.41 -1.51 -1.67 -2.13 -4.14 -4.61 -4.29 -3.16 -3.07
Net Income / (Loss) Continuing Operations		 -2.85 -2.13 -1.81 -2.13 -2.44 -3.26 -6.73 -6.31 -5.09 -3.59 -6.01
Consolidated Net Income / (Loss)		 -2.85 -2.13 -1.81 -2.13 2.44 -3.26 -6.73 -6.31 -5.09 -3.59 -6.01
Non-Cash Adjustments To Reconcile Net Income		 0.65 0.45 0.26 0.74 -0.75 1.10 2.59 1.64 0.83 0.57 2.52
Changes in Operating Assets and Liabilities, net		 0.03 0.01 0.14 -0.12 -0.02 0.04 -0.00 0.06 -0.04 -0.15 0.42
Net Cash From Investing Activities		 0.11 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.17
Net Cash From Continuing Investing Activities		 0.11 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3.17
Purchase of Investments		 - - - - - - - - - 0.00 -0.44
Other Investing Activities, net		 0.11 0.10 - - - - - - - 0.00 -2.73
Net Cash From Financing Activities		 2.05 1.75 2.52 4.48 0.00 4.60 3.90 5.14 3.14 0.00 10
Net Cash From Continuing Financing Activities		 2.05 1.75 2.52 4.48 0.00 4.60 3.90 5.14 3.14 0.00 10
Issuance of Common Equity		 - 0.00 2.50 4.50 0.00 4.60 3.69 5.14 3.14 0.00 10
Other Financing Activities, net		 0.32 0.00 0.02 0.00 - - 0.22 0.00 0.01 0.00 0.05
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.02 0.01
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Lixte Biotechnology

This table details how cash moves in and out of Lixte Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 2.19 -0.90 -0.79 -0.82 -0.96 -0.60 0.35 -0.50 2.00 2.22 -1.86
Net Cash From Operating Activities		 -0.94 -0.90 -0.79 -0.82 -0.96 -0.60 -0.57 -0.49 -0.93 -1.09 -1.83
Net Cash From Continuing Operating Activities		 -0.94 -0.90 -0.79 -0.82 -0.96 -0.60 -0.57 -0.49 -0.93 -1.09 -1.86
Net Income / (Loss) Continuing Operations		 -1.02 -1.03 -0.97 -1.01 -0.99 -0.62 -0.71 -0.78 -1.98 -2.54 -1.99
Consolidated Net Income / (Loss)		 -1.02 -1.03 -0.97 -1.01 -0.99 -0.62 -0.71 -0.78 -1.98 -2.54 -1.99
Non-Cash Adjustments To Reconcile Net Income		 0.17 0.17 0.16 0.28 0.07 0.06 0.11 0.28 0.98 1.15 0.20
Changes in Operating Assets and Liabilities, net		 -0.09 -0.04 0.02 -0.09 -0.04 -0.04 0.03 0.01 0.07 0.30 -0.08
Net Cash From Investing Activities		 - - 0.00 - - - 0.00 - -2.64 -0.54 -0.02
Net Cash From Continuing Investing Activities		 - - 0.00 - - - 0.00 - -2.64 -0.54 0.00
Net Cash From Financing Activities		 3.14 - 0.00 - - - 0.91 -0.01 5.56 3.84 0.00
Net Cash From Continuing Financing Activities		 3.14 - 0.00 - - - 0.91 -0.01 5.56 3.84 0.00
Issuance of Common Equity		 - -0.00 0.00 - - - 0.91 - 5.51 3.84 0.00
Cash Interest Paid		 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Balance Sheets for Lixte Biotechnology

This table presents Lixte Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.60 0.43 1.37 4.34 2.67 5.23 5.09 5.56 4.31 1.15 13
Total Current Assets		 0.60 0.43 1.37 4.33 2.67 5.23 5.09 5.56 4.23 1.15 5.18
Cash & Equivalents		 0.03 0.20 1.31 4.27 2.60 5.07 4.82 5.35 4.20 1.04 5.11
Prepaid Expenses		 0.27 0.23 0.06 0.06 0.06 0.08 0.12 0.06 0.03 0.11 0.07
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.58
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.00 0.97
Other Noncurrent Operating Assets		 - - 0.00 0.00 - - - - 0.08 0.00 0.97
Total Liabilities & Shareholders' Equity		 0.60 0.43 1.37 4.34 2.67 5.23 5.09 5.56 4.31 1.15 13
Total Liabilities		 0.29 0.22 0.37 0.21 0.24 0.22 0.30 0.40 0.31 0.32 1.77
Total Current Liabilities		 0.29 0.22 0.37 0.21 0.24 0.22 0.30 0.40 0.31 0.32 1.33
Accounts Payable		 0.16 0.16 0.31 0.20 0.14 0.19 0.23 0.23 0.16 0.08 0.44
Other Current Liabilities		 0.12 0.06 0.06 0.02 0.09 0.02 0.08 0.17 0.16 0.24 0.90
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.44
Other Noncurrent Operating Liabilities		 - - - - - - - - - 0.00 0.44
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.31 0.21 1.00 4.13 2.43 5.01 4.79 5.17 3.99 0.83 11
Total Preferred & Common Equity		 0.31 0.21 1.00 4.13 2.43 5.01 4.79 5.17 3.99 0.83 9.66
Preferred Stock		 1.75 3.50 3.50 3.50 3.50 3.50 3.50 3.50 3.50 3.50 1.73
Total Common Equity		 -1.44 -3.29 -2.50 0.63 -1.07 1.51 1.29 1.67 0.49 -2.67 7.93
Common Stock		 17 17 20 25 26 32 38 45 49 49 66
Retained Earnings		 -19 -21 -23 -25 -27 -30 -37 -43 -48 -52 -58
Other Equity Adjustments		 - - - - - - - - - 0.00 0.00
Noncontrolling Interest		 - - - - - - - - - 0.00 1.30

Quarterly Balance Sheets for Lixte Biotechnology

This table presents Lixte Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 5.23 3.59 2.67 1.70 1.51 1.19 5.43 11
Total Current Assets		 5.23 3.59 2.67 1.69 1.50 0.99 5.43 3.41
Cash & Equivalents		 5.11 3.41 2.60 1.64 1.38 0.89 2.89 3.25
Prepaid Expenses		 0.05 0.10 0.07 0.05 0.11 0.10 0.09 0.16
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.61
Total Noncurrent Assets		 0.00 0.00 0.00 0.01 0.02 0.20 0.00 0.85
Other Noncurrent Operating Assets		 - - - 0.01 0.02 0.20 - 0.85
Total Liabilities & Shareholders' Equity		 5.23 3.59 2.67 1.70 1.51 1.19 5.43 11
Total Liabilities		 0.31 0.46 0.42 0.33 0.36 0.54 0.52 1.69
Total Current Liabilities		 0.31 0.46 0.42 0.33 0.36 0.54 0.52 1.22
Accounts Payable		 0.22 0.25 0.13 0.07 0.11 0.09 0.24 0.39
Other Current Liabilities		 0.09 0.22 0.29 0.26 0.24 0.26 0.29 0.83
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.46
Other Noncurrent Operating Liabilities		 - - - - - - - 0.46
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 4.92 3.13 2.25 1.37 1.16 0.65 4.91 9.18
Total Preferred & Common Equity		 4.92 3.13 2.25 1.37 1.16 0.65 4.91 7.95
Preferred Stock		 3.50 3.50 3.50 3.50 3.50 0.00 2.55 0.00
Total Common Equity		 1.42 -0.37 -1.25 -2.13 -2.34 0.65 2.36 7.95
Common Stock		 49 49 49 49 50 54 58 68
Retained Earnings		 -47 -49 -50 -51 -53 -54 -56 -60
Other Equity Adjustments		 - - - - - - 0.00 0.00
Noncontrolling Interest		 - - - - - - - 1.23

Annual Metrics And Ratios for Lixte Biotechnology

This table displays calculated financial ratios and metrics derived from Lixte Biotechnology's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 47,875,814.00 47,875,814.00 58,025,814.00 58,045,814.00 67,045,814.00 67,045,814.00 13,746,593.00 16,646,593.00 2,249,290.00 2,249,290.00 5,704,200.00
DEI Adjusted Shares Outstanding		 797,930.00 797,930.00 967,097.00 967,430.00 1,117,430.00 1,117,430.00 1,374,659.00 1,664,659.00 2,249,290.00 2,249,290.00 5,704,200.00
DEI Earnings Per Adjusted Shares Outstanding		 -3.58 -2.68 -1.87 -2.20 -2.18 -2.92 -4.89 -3.79 -2.26 -1.59 -1.07
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -3.11% 25.15% 15.23% -18.14% -16.46% -31.14% -105.83% 6.05% 19.42% 29.72% -67.99%
EBIT Growth		 -3.11% 25.15% 15.23% -18.14% -16.46% -31.14% -105.83% 6.05% 19.42% 29.72% -67.99%
NOPAT Growth		 -10.12% 19.33% 15.23% -18.14% -16.46% -31.18% -105.74% 6.09% 19.35% 29.81% -42.96%
Net Income Growth		 -3.11% 25.15% 15.29% -17.96% -14.40% -33.79% -106.08% 6.18% 19.41% 29.51% -67.58%
EPS Growth		 0.00% 33.33% 25.00% -33.33% -450.00% -31.82% 0.00% 0.00% 33.33% 40.23% 20.75%
Operating Cash Flow Growth		 -33.36% 23.09% 15.81% -7.00% 210.79% -227.31% -94.37% -11.32% 6.91% 26.29% 2.97%
Free Cash Flow Firm Growth		 10.38% 36.45% 22.86% -76.37% -3.94% -38.74% -97.51% 9.83% 16.90% 29.49% -285.99%
Invested Capital Growth		 30.53% -94.87% -2,194.98% 52.63% -11.92% 65.21% 41.71% -463.25% -10.93% -1.44% 2,865.12%
Revenue Q/Q Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -0.68% 4.37% 3.48% 4.43% 0.86% -21.27% -20.04% 5.82% 10.68% 10.34% -54.19%
EBIT Q/Q Growth		 -0.68% 4.37% 3.48% 4.43% 0.86% -21.27% -20.04% 5.82% 10.68% 10.34% -54.19%
NOPAT Q/Q Growth		 2.03% 4.37% 3.48% 4.43% 0.86% -21.31% -20.01% 5.85% 10.65% 10.35% -31.08%
Net Income Q/Q Growth		 -0.68% 4.37% 4.42% 3.79% 1.08% -21.82% -20.02% 5.93% 10.54% 10.36% -47.17%
EPS Q/Q Growth		 0.00% 0.00% 25.00% 0.00% -450.00% 23.68% 0.00% 5.93% 2.92% 10.67% -88.06%
Operating Cash Flow Q/Q Growth		 1.45% 7.83% 11.61% -23.99% 189.37% -235.04% -10.92% -1.35% 6.66% 8.75% -18.95%
Free Cash Flow Firm Q/Q Growth		 -1.42% -16.92% 10.26% -20.92% 10.43% -10.33% -19.12% 3.71% 10.45% 7.54% -91.96%
Invested Capital Q/Q Growth		 -50.79% -78.26% -59.00% 62.11% 25.19% -188.62% -129.24% -24.86% -14.28% 21.78% 189.21%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -1,426.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -1,323.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -1,426.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -1,426.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 99.99% 99.92% 99.77% 98.00% 99.98% 100.10% 99.96% 99.98% 100.27% 100.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -725.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 2,227.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -260.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -986.56% -810.00% -298.96% -83.31% -74.40% -87.69% -137.28% -126.81% -111.07% -148.73% -101.95%
Cash Return on Invested Capital (CROIC)		 -752.23% -803.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -164.68%
Operating Return on Assets (OROA)		 -501.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -501.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 1,999.41% 7,257.85% 1,430.85% 30.57% 4.99% -5.25% -39.25% -37.65% -26.19% 67.18% -45.49%
Return on Equity Simple (ROE_SIMPLE)		 -913.16% -994.01% -181.74% -51.70% -100.26% -65.14% -140.46% -122.21% -127.34% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.85 -1.49 -1.27 -1.50 -1.74 -2.29 -4.70 -4.42 -3.56 -2.50 -3.58
NOPAT Margin		 -926.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2,953.43% -573.71% -71.94% -22.82% -20.29% -25.52% -40.92% -37.23% -31.89% -41.39% -79.21%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -89.20% -302.33% -32.62%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 377.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 1,045.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 1,423.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.85 -2.13 -1.81 -2.14 -2.49 -3.27 -6.72 -6.31 -5.09 -3.58 -6.01
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.85 -2.13 -1.81 -2.14 -2.49 -3.27 -6.72 -6.31 -5.09 -3.58 -6.01
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 74.20 0.00 23.43 12.68 5.09 10.68 0.00 2.83
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 74.20 0.00 23.43 12.68 5.09 10.68 0.00 2.83
Price to Revenue (P/Rev)		 35.91 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 30.81 706.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.47
Enterprise Value to Revenue (EV/Rev)		 44.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 27.73 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.12 -0.42 -1.24 -1.09 -1.05 -1.03 -1.01 -1.02 -1.04 -1.09 -0.52
Leverage Ratio		 1.97 1.96 1.49 1.11 1.07 1.06 1.05 1.07 1.08 1.13 1.18
Compound Leverage Factor		 1.97 1.96 1.49 1.11 1.05 1.06 1.05 1.07 1.08 1.13 1.18
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 560.30% 1,629.73% 351.74% 84.83% 143.79% 69.83% 73.06% 67.76% 87.61% 423.10% 15.80%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11.84%
Common Equity to Total Capital		 -460.30% -1,529.73% -251.74% 15.17% -43.79% 30.17% 26.94% 32.24% 12.39% -323.10% 72.37%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -43.18 -62.84 -12.53 123.66 98.64 89.12 18.98 -0.71 -8.45 -64.47 0.01
Noncontrolling Interest Sharing Ratio		 302.67% 996.03% 578.61% 136.70% 106.71% 94.01% 71.41% 70.31% 76.42% 145.17% 55.38%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.09 1.98 3.67 20.55 11.23 24.15 16.81 14.05 13.48 3.60 3.88
Quick Ratio		 0.09 0.91 3.50 20.26 10.98 23.41 15.92 13.53 13.39 3.26 3.83
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.92 -1.22 -0.94 -1.66 -1.73 -2.39 -4.73 -4.26 -3.54 -2.50 -9.64
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -651.58 -637.74 -480.37 -218.23 -148.50 -1,052.82
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -580.13 -558.80 -519.63 -264.48 -188.13 -335.29
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -580.13 -558.80 -519.63 -264.48 -188.13 -335.29
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.29 0.01 -0.31 -0.15 -0.16 -0.06 -0.03 -0.19 -0.21 -0.21 5.85
Invested Capital Turnover		 0.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.07 -0.27 -0.33 0.16 -0.02 0.11 0.02 -0.15 -0.02 -0.00 6.07
Enterprise Value (EV)		 8.91 10 11 46 46 34 15 6.62 4.58 7.03 20
Market Capitalization		 7.18 7.18 8.70 46 46 35 16 8.47 5.29 4.57 22
Book Value per Share		 ($0.03) ($0.07) ($0.04) $0.01 ($0.02) $0.02 $0.09 $0.10 $0.22 ($1.19) $1.39
Tangible Book Value per Share		 ($0.03) ($0.07) ($0.04) $0.01 ($0.02) $0.02 $0.09 $0.10 $0.22 ($1.19) $1.39
Total Capital		 0.31 0.21 1.00 4.13 2.43 5.01 4.79 5.17 3.99 0.83 11
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.03 -0.20 -1.31 -4.27 -2.60 -5.07 -4.82 -5.35 -4.20 -1.04 -5.11
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.29 0.01 -0.31 -0.15 -0.16 -0.06 -0.03 -0.19 -0.29 -0.21 -1.26
Debt-free Net Working Capital (DFNWC)		 0.31 0.21 1.00 4.12 2.43 5.01 4.79 5.17 3.92 0.83 3.85
Net Working Capital (NWC)		 0.31 0.21 1.00 4.12 2.43 5.01 4.79 5.17 3.92 0.83 3.85
Net Nonoperating Expense (NNE)		 1.00 0.64 0.54 0.64 0.70 0.98 2.02 1.89 1.52 1.09 2.43
Net Nonoperating Obligations (NNO)		 -0.02 -0.20 -1.31 -4.27 -2.60 -5.07 -4.82 -5.35 -4.20 -1.04 -5.11
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 143.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 156.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 156.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.60) ($2.40) ($1.80) ($2.40) ($2.40) ($2.90) ($5.00) ($4.00) ($2.66) ($1.59) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 759.60K 864.60K 967.10K 1.12M 1.12M 1.35M 1.37M 1.58M 1.92M 2.25M 11.62M
Adjusted Diluted Earnings per Share		 ($3.60) ($2.40) ($1.80) ($2.40) ($2.40) ($2.90) ($5.00) $0.00 ($2.66) ($1.59) ($1.26)
Adjusted Weighted Average Diluted Shares Outstanding		 759.60K 864.60K 967.10K 1.12M 1.12M 1.35M 1.37M 1.67M 1.92M 2.25M 4.84M
Adjusted Basic & Diluted Earnings per Share		 ($3.60) ($2.40) ($1.80) ($2.40) ($2.40) ($2.90) ($5.00) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 779.89K 797.93K 930.29K 979.94K 1.12M 1.13M 1.35M 1.67M 2.25M 2.68M 11.62M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.85 -1.49 -1.27 -1.50 -1.74 -2.29 -4.19 -3.53 -3.56 -2.50 -3.58
Normalized NOPAT Margin		 -926.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -1,426.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -888.83 -906.61 -711.53 -313.45 -212.60 -656.01
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -622.35 -634.52 -497.81 -219.50 -148.68 -390.41
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -888.83 -906.61 -711.53 -313.45 -212.60 -656.01
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -622.35 -634.52 -497.81 -219.50 -148.68 -390.41
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.09% 0.00% -1.16% 0.00% 0.00% -0.16% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Lixte Biotechnology

This table displays calculated financial ratios and metrics derived from Lixte Biotechnology's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 2,249,290.00 2,249,290.00 2,249,290.00 2,249,290.00 2,249,290.00 2,249,290.00 2,684,074.00 2,684,074.00 4,561,363.00 5,704,200.00 11,617,944.00
DEI Adjusted Shares Outstanding		 2,249,290.00 2,249,290.00 2,249,290.00 2,249,290.00 2,249,290.00 2,249,290.00 2,684,074.00 2,684,074.00 4,561,363.00 5,704,200.00 11,617,944.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.45 -0.46 -0.43 -0.45 -0.44 -0.27 -0.26 -0.29 -0.45 -0.45 -0.17
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 30.78% 37.23% 29.36% 39.55% 3.70% 40.18% 26.90% 23.27% -82.63% -344.00% -181.23%
EBIT Growth		 30.78% 37.23% 29.36% 39.55% 3.70% 40.18% 26.90% 23.27% -82.63% -344.00% -181.23%
NOPAT Growth		 30.73% 37.16% 29.43% 39.57% 4.00% 40.20% 26.88% 23.22% -83.20% -197.40% -181.13%
Net Income Growth		 31.07% 36.72% 28.98% 39.41% 3.21% 40.16% 26.95% 23.27% -100.85% -311.84% -180.12%
EPS Growth		 44.94% 47.57% 47.56% 55.00% 10.20% 57.41% 32.56% 35.56% 25.00% -52.17% 37.93%
Operating Cash Flow Growth		 19.55% 25.35% 37.92% 30.32% -1.40% 33.64% 27.97% 40.48% 3.22% -81.72% -222.15%
Free Cash Flow Firm Growth		 11.04% 29.40% 68.45% 51.54% 12.37% 38.87% -40.56% -13.50% -492.43% -1,622.06% -1,254.07%
Invested Capital Growth		 -21.20% -10.93% -3,751.45% -58.40% -48.20% -1.44% 21.65% 32.46% 847.86% 2,865.12% 2,728.02%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 38.63% -0.17% 5.76% -4.34% 2.24% 37.78% -15.17% -9.53% -132.68% -51.27% 27.05%
EBIT Q/Q Growth		 38.63% -0.17% 5.76% -4.34% 2.24% 37.78% -15.17% -9.53% -132.68% -51.27% 27.05%
NOPAT Q/Q Growth		 38.67% -0.17% 5.75% -4.37% 2.57% 37.61% -15.23% -9.60% -132.49% -1.29% -8.93%
Net Income Q/Q Growth		 38.94% -1.32% 5.90% -4.08% 2.46% 37.36% -14.87% -9.32% -155.31% -28.45% 21.87%
EPS Q/Q Growth		 51.00% -10.20% 20.37% -4.65% 2.22% 47.73% -26.09% 0.00% -13.79% -6.06% 48.57%
Operating Cash Flow Q/Q Growth		 19.65% 4.48% 12.51% -3.78% -16.92% 37.48% 5.04% 14.25% -90.11% -17.39% -68.34%
Free Cash Flow Firm Q/Q Growth		 42.54% -1.84% 43.18% -45.74% -3.90% 28.95% -30.66% -17.68% -442.33% -106.51% -2.74%
Invested Capital Q/Q Growth		 17.12% -14.28% -37.93% -21.25% 22.46% 21.78% -6.53% -4.52% 958.68% 189.21% 1.25%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 110.17% 93.29% 100.00%
Interest Burden Percent		 99.46% 100.60% 100.45% 100.19% 99.96% 100.64% 100.38% 100.19% 99.78% 100.06% 99.99%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -100.34% -111.07% -130.17% -163.33% -127.20% -148.73% -155.14% -213.21% -130.06% -101.95% -140.99%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -248.11% -164.68% -179.24%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -38.37% -26.19% -3.74% 68.17% 14.36% 67.18% 98.27% 44.33% -4.68% -45.49% -76.43%
Return on Equity Simple (ROE_SIMPLE)		 -115.50% 0.00% -150.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.72 -0.72 -0.68 -0.71 -0.69 -0.43 -0.49 -0.54 -1.26 -1.28 -1.39
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.17% -6.57% -7.85% -11.06% -8.83% -7.18% -8.95% -13.40% -31.80% -41.22% -25.73%
Return On Investment Capital (ROIC_SIMPLE)		 - -17.98% -21.65% -31.45% -50.35% -51.91% -42.69% -83.25% -25.67% -11.65% -15.16%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.02 -1.03 -0.97 -1.01 -0.99 -0.61 -0.71 -0.77 -1.80 -2.73 -1.99
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.02 -1.03 -0.97 -1.01 -0.99 -0.61 -0.71 -0.77 -1.80 -2.73 -1.99
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.87 10.68 0.00 0.00 0.00 0.00 0.00 3.73 9.73 2.83 4.49
Price to Tangible Book Value (P/TBV)		 3.87 10.68 0.00 0.00 0.00 0.00 0.00 3.73 9.73 2.83 4.49
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.17 3.47 5.68
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.04 -1.04 -1.12 -1.07 -1.09 -1.12 -1.20 -0.72 -0.52 -0.45
Leverage Ratio		 1.06 1.08 1.10 1.17 1.10 1.13 1.19 1.33 1.14 1.18 1.20
Compound Leverage Factor		 1.06 1.08 1.10 1.17 1.10 1.14 1.20 1.33 1.13 1.18 1.20
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 71.10% 87.61% 111.95% 155.82% 256.05% 423.10% 301.95% 0.00% 51.98% 15.80% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11.84% 13.44%
Common Equity to Total Capital		 28.90% 12.39% -11.95% -55.82% -156.05% -323.10% -201.95% 100.00% 48.02% 72.37% 86.56%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.60 -5.34 -9.28 -19.13 -35.76 -55.93 -43.94 -62.06 12.08 0.86 4.59
Noncontrolling Interest Sharing Ratio		 61.76% 76.42% 97.13% 141.74% 111.29% 145.17% 163.34% 120.79% 96.40% 55.38% 45.79%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 16.79 13.48 7.75 6.33 5.13 3.60 4.22 1.84 10.42 3.88 2.78
Quick Ratio		 16.38 13.39 7.38 6.16 4.98 3.26 3.90 1.65 5.54 3.83 2.65
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.68 -0.70 -0.40 -0.58 -0.60 -0.43 -0.56 -0.66 -3.56 -7.34 -7.54
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -2,455.11 -68.76 -55.16 -139.07 -572.20 -96.22 -177.73 -362.26 -7,781.22 -1,955.16 -2,436.92
Operating Cash Flow to Interest Expense		 -3,384.91 -88.92 -109.83 -197.17 -912.86 -135.08 -181.33 -269.33 -2,027.90 -289.64 -591.53
Operating Cash Flow Less CapEx to Interest Expense		 -3,384.91 -88.92 -109.83 -197.17 -912.86 -135.08 -181.33 -269.33 -2,027.90 -289.64 -591.53
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.18 -0.21 -0.29 -0.35 -0.27 -0.21 -0.23 -0.24 2.02 5.85 5.93
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.03 -0.02 -0.28 -0.13 -0.09 -0.00 0.06 0.11 2.30 6.07 6.15
Enterprise Value (EV)		 3.91 4.58 7.69 6.24 6.07 7.03 5.36 1.54 23 20 34
Market Capitalization		 5.51 5.29 7.60 5.33 4.21 4.57 3.25 2.43 23 22 36
Book Value per Share		 $0.63 $0.22 ($0.17) ($0.56) ($0.95) ($1.19) ($0.87) $0.24 $0.52 $1.39 $1.39
Tangible Book Value per Share		 $0.63 $0.22 ($0.17) ($0.56) ($0.95) ($1.19) ($0.87) $0.24 $0.52 $1.39 $1.39
Total Capital		 4.92 3.99 3.13 2.25 1.37 0.83 1.16 0.65 4.91 11 9.18
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -5.11 -4.20 -3.41 -2.60 -1.64 -1.04 -1.38 -0.89 -2.89 -5.11 -3.25
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.18 -0.29 -0.29 -0.35 -0.28 -0.21 -0.24 -0.43 2.02 -1.26 -1.07
Debt-free Net Working Capital (DFNWC)		 4.92 3.92 3.13 2.25 1.36 0.83 1.14 0.45 4.91 3.85 2.18
Net Working Capital (NWC)		 4.92 3.92 3.13 2.25 1.36 0.83 1.14 0.45 4.91 3.85 2.18
Net Nonoperating Expense (NNE)		 0.30 0.31 0.29 0.30 0.30 0.19 0.21 0.23 0.72 1.27 0.60
Net Nonoperating Obligations (NNO)		 -5.11 -4.20 -3.41 -2.60 -1.64 -1.04 -1.38 -0.89 -2.89 -5.11 -3.25
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.49) ($0.54) ($0.43) ($0.45) ($0.44) ($0.23) ($0.29) ($0.29) ($0.33) $0.00 ($0.18)
Adjusted Weighted Average Basic Shares Outstanding		 2.07M 1.92M 2.25M 2.25M 2.25M 2.68M 2.47M 2.72M 6.17M 11.62M 10.89M
Adjusted Diluted Earnings per Share		 ($0.49) ($0.54) ($0.43) ($0.45) ($0.44) ($0.23) ($0.29) ($0.29) ($0.33) ($0.35) ($0.18)
Adjusted Weighted Average Diluted Shares Outstanding		 2.07M 1.92M 2.25M 2.25M 2.25M 2.25M 2.47M 2.72M 6.17M 4.84M 10.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.54) $0.00 $0.00 $0.00 ($0.23) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.25M 2.25M 2.25M 2.25M 2.25M 2.68M 2.68M 4.56M 5.70M 11.62M 12.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.72 -0.72 -0.68 -0.71 -0.69 -0.43 -0.49 -0.54 -1.26 -1.28 -1.39
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3,671.29 -101.14 -134.57 -242.90 -940.34 -138.49 -225.47 -427.75 -3,941.98 -725.55 -642.08
NOPAT to Interest Expense		 -2,569.63 -70.79 -94.19 -170.06 -656.13 -96.90 -157.85 -299.65 -2,759.19 -340.03 -449.35
EBIT Less CapEx to Interest Expense		 -3,671.29 -101.14 -134.57 -242.90 -940.34 -138.49 -225.47 -427.75 -3,941.98 -725.55 -642.08
NOPAT Less CapEx to Interest Expense		 -2,569.63 -70.79 -94.19 -170.06 -656.13 -96.90 -157.85 -299.65 -2,759.19 -340.03 -449.35
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Lixte Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Lixte Biotechnology's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Lixte Biotechnology's net income appears to be on an upward trend, with a most recent value of -$6.01 million in 2025, rising from -$2.85 million in 2015. The previous period was -$3.59 million in 2024. Check out Lixte Biotechnology's forecast to explore projected trends and price targets.

Lixte Biotechnology's total operating income in 2025 was -$5.11 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $5.11 million

Over the last 10 years, Lixte Biotechnology's total revenue changed from $200 thousand in 2015 to $0.00 in 2025, a change of -100.0%.

Lixte Biotechnology's total liabilities were at $1.77 million at the end of 2025, a 456.8% increase from 2024, and a 520.4% increase since 2015.

In the past 10 years, Lixte Biotechnology's cash and equivalents has ranged from $25.28 thousand in 2015 to $5.35 million in 2022, and is currently $5.11 million as of their latest financial filing in 2025.

Over the last 10 years, Lixte Biotechnology's book value per share changed from -0.03 in 2015 to 1.39 in 2025, a change of -4,735.3%.


Related Companies

Financial statements for NASDAQ:LIXT last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
A better retirement stock than Berkshire?
Whitney Tilson - the analyst CNBC called 'The Prophet' for early calls on Netflix, Apple, and Amazon - says he...
Stansberry Research | Sponsoredtc pixel
Executive order could send gold to 6,000 per ounce
Executive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...
Cedar Gold Group | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel